Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theriva Biologics ( (TOVX) ) has shared an announcement.
On October 6, 2025, Theriva Biologics announced the presentation of preclinical data for VCN-12, a next-generation oncolytic adenovirus, at the 32nd Annual Congress of the European Society of Gene & Cell Therapy. The data highlights a novel mechanism that could improve antitumor effects. Additionally, results from a preclinical study on VCN-01’s intracranial administration were published, supporting its further development for treating brain tumors. These developments could enhance Theriva’s positioning in cancer therapeutics, potentially benefiting stakeholders by advancing treatment options for brain tumors.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
Spark’s Take on TOVX Stock
According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.
Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.
To see Spark’s full report on TOVX stock, click here.
More about Theriva Biologics
Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, particularly in areas with high unmet needs. The company is advancing a new oncolytic adenovirus platform for various delivery methods to enhance tumor cell death and immune response. Its lead candidates include VCN-01, an oncolytic adenovirus, SYN-004 for microbiome protection, and SYN-020 for gastrointestinal and systemic diseases.
Average Trading Volume: 581,907
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.99M
See more insights into TOVX stock on TipRanks’ Stock Analysis page.